VTRS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Viatris Inc (VTRS) is not a strong buy for a beginner, long-term investor at this moment. While the stock has some positive catalysts such as analyst upgrades and a growing product pipeline, the company's financial performance shows declining net income, EPS, and gross margin, which raises concerns about its long-term profitability. Additionally, hedge fund selling and lack of strong technical or proprietary trading signals further support a cautious approach. The stock is better suited for monitoring rather than immediate investment.
The technical indicators present a mixed picture. The MACD is negative and expanding downward, indicating bearish momentum. RSI is neutral at 34.388, not signaling overbought or oversold conditions. However, moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting some upward trend potential. The stock is trading near its support level (S1: 15.315), but pre-market price at 15.11 is below this level, which could indicate further downside risk.
Analyst upgrades: UBS upgraded the stock to Buy with an $18 price target, citing improving growth, cost savings, and a strong product pipeline. Barclays also initiated coverage with an Overweight rating.
Dividend declaration: Quarterly dividend of $0.12 per share adds to shareholder value.
New product launches and cost-saving initiatives could unlock future value.
Hedge fund selling has increased significantly (247.32% over the last quarter).
Financial performance is weak, with declining net income (-34.15% YoY), EPS (-30.23% YoY), and gross margin (-21.62% YoY).
Workforce reduction of 10% may create short-term operational challenges.
In Q4 2025, revenue increased by 4.97% YoY to $3.7 billion, but net income dropped to -$340.1 million (-34.15% YoY). EPS also declined to -$0.3 (-30.23% YoY), and gross margin fell to 30.99% (-21.62% YoY). While revenue growth is positive, the declining profitability metrics are concerning.
Analyst sentiment is improving, with recent upgrades from UBS (Buy, $18 target) and Barclays (Overweight, $15 target). However, some analysts remain neutral, reflecting mixed views on the stock's near-term potential. Price targets range from $12 to $18, with a median target of $15.50.
